KOD - Kodiak Sciences Inc.

2.35
-0.050   -2.128%

Share volume: 541,891
Last Updated: 04-04-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.06%

PREVIOUS CLOSE
CHG
CHG%
$2.40
-0.05
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 0%
Dept financing 15%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-11.99%
1 Month
-35.08%
3 Months
-43.24%
6 Months
-43.24%
1 Year
-43.24%
2 Year
-43.24%
Key data
Stock price
$2.35
P/E Ratio 
0.00
DAY RANGE
$2.10 - $2.36
EPS 
-$0.83
52 WEEK RANGE
$2.10 - $4.30
52 WEEK CHANGE
-$43.24
MARKET CAP 
523.607 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$440,724
AVERAGE 30 VOLUME 
$381,979
Company detail
CEO: Victor Perlroth
Region: US
Website: kodiak.com
Employees: 90
IPO year: 2018
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD) The company was formerly known as Oligasis, LLC.

Recent news
loading